• Cadent (Carlstadt, New Jersey) reported future product and service updates in its line of OrthoCAD devices. These products provide 3-D digital solutions for the orthodontic industry. The enhanced services include impression tray replenishment and bracket storage, as well as a partnership to provide discounted pricing for ancillary orthodontic supplies. Cadent is a provider of 3-D digital solutions for the orthodontic and dental industries.

• Fletcher-Flora Health Care Systems (Anaheim, California) reported the release of FFlex eSuite, the latest addition to its line of web-based laboratory information system (LIS) solutions for the clinical laboratory. FFlex eSuite offers LIS solutions to any size laboratory, from small clinics and group practices to the largest multi-facility reference laboratories, the company said. “The beauty of FFlex eSuite is in its modularity. It can be configured to meet the needs of the simplest to the most complex laboratory environments,” said Neal Flora, president/CEO of Fletcher-Flora. “All modules are completely Web-based, with proven core software technology facilitating deployments over a Local Area Network, Wide Area Network and the Internet. Customers choose the options that are right for their laboratory essentially customizing a system to best fit their specific needs. FFlex eSuite is specially designed to streamline and simplify the integration of clinical instruments, printing devices, satellite facilities and third-party systems, and does so in a way that facilitates communication and eases workflow. FFlex eSuite provides the solutions for today’s laboratories and the flexibility to support their future growth.” Fletcher Flora produces Laboratory Information System solutions for physician offices, group practices and hospital laboratories.

• Third Wave Technologies (Madison, Wisconsin) reported that it has submitted a 510(k) application to the FDA for its InPlex Cystic Fibrosis Molecular Test. The test is designed to simultaneously detect and identify mutations and variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene in genomic DNA samples isolated from human whole peripheral blood specimens. This test is a qualitative genotyping test intended to provide information to determine CF carrier status in adults, as an aid in newborn screening and in confirmatory diagnostic testing in newborns and children. Third Wave produces molecular diagnostic reagents for a variety of DNA and RNA analysis.

No Comments